Zydus Lifesciences Completes Share Subscription in Torrent Urja 25 Private Limited
Zydus Lifesciences Limited, along with its various subsidiaries, has completed the subscription of equity shares in Torrent Urja 25 Private Limited. This investment follows a multi-tranche agreement, marking the consummation of the transaction on May 19, 2026.The subscription agreement between Zydus Lifesciences Limited and its subsidiaries covered four tranches of equity shares. Initially, the company and its subsidiaries had invested an aggregate amount of Rs. 38.65 million for the subscription of 38,64,792 equity shares under Tranche 1 of Torrent Urja 25. This investment represented 22.06% of the company's paid-up share capital.
The transaction was further advanced on May 19, 2026, when Zydus Lifesciences Limited and its subsidiaries invested the remaining amount of Rs. 90.18 million. This investment secured 90,17,848 equity shares under Tranches 2, 3, and 4, also representing 22.06% of the paid-up share capital of Torrent Urja 25.
The total subscription of shares in Torrent Urja 25 was consummated entirely on May 19, 2026, fulfilling the terms of the Share Subscripition and Shareholders' Agreements (SSSAs).
The transaction details are summarized below:
| Tranche | Investment Amount | Equity Shares Subscribed | Percentage of Paid-up Share Capital |
|---|---|---|---|
| Tranche 1 | Rs. 38.65 million | 38,64,792 | 22.06% |
| Tranche 2, 3, & 4 | Rs. 90.18 million | 90,17,848 | 22.06% |
The investment marks a significant commitment by Zydus Lifesciences Limited to Torrent Urja 25 Private Limited.
ZYDUSLIFE Stock Price Movement
Shares of Zydus Lifesciences Limited are edging higher to ₹1055.9 as of 12:36 PM today, having gained 3.63% in live trading. The stock continues its rally, hitting its 52-week high of ₹1093.65 amid significant activity, with 11.20 million shares traded so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.